DOXORUBICIN Drug Patent Profile
✉ Email this page to a colleague
When do Doxorubicin patents expire, and when can generic versions of Doxorubicin launch?
Doxorubicin is a drug marketed by Qilu Pharm Hainan, Actavis Inc, Almaject, Amneal, Fresenius Kabi Usa, Gland, Hikma, Hisun Pharm Hangzhou, Hlthcare, Mylan Labs Ltd, Pfizer, Pharmachemie Bv, Pharmobedient, Sagent Pharms, Sun Pharm Inds, Teva Pharms Usa, Alembic, Ayana Pharma Ltd, Baxter Hlthcare Corp, Dr Reddys, Lupin, Sun Pharm, and Zydus Lifesciences. and is included in twenty-seven NDAs.
The generic ingredient in DOXORUBICIN is doxorubicin hydrochloride. There are seventeen drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the doxorubicin hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Doxorubicin
A generic version of DOXORUBICIN was approved as doxorubicin hydrochloride by PFIZER on December 23rd, 1987.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for DOXORUBICIN?
- What are the global sales for DOXORUBICIN?
- What is Average Wholesale Price for DOXORUBICIN?
Summary for DOXORUBICIN
| US Patents: | 0 |
| Applicants: | 23 |
| NDAs: | 27 |
| Drug Prices: | Drug price information for DOXORUBICIN |
| DailyMed Link: | DOXORUBICIN at DailyMed |
US Patents and Regulatory Information for DOXORUBICIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baxter Hlthcare Corp | DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL) | doxorubicin hydrochloride | INJECTABLE, LIPOSOMAL;INJECTION | 212219-002 | Oct 19, 2022 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Sagent Pharms | DOXORUBICIN HYDROCHLORIDE | doxorubicin hydrochloride | INJECTABLE;INJECTION | 091495-001 | Mar 18, 2013 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Zydus Lifesciences | DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL) | doxorubicin hydrochloride | INJECTABLE, LIPOSOMAL;INJECTION | 212299-002 | Sep 10, 2020 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
